Trial Profile
A Phase I Study of Panobinostat in Combination With Bortezomib in the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Panobinostat (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- Acronyms BUS48T
- 18 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Jan 2012 New trial record